Dr. Elterman discusses Aquablation treatment for BPH

The guideline includes 38 recommendations on managing incontinence following treatment for localized prostate cancer or benign prostatic hyperplasia.

Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.

“Over the 4-year period since first-line protocol therapy initiation, [patients treated with] nivolumab plus cabozantinib achieved a 1.5-times longer mean TFS vs sunitinib," says Charlene Mantia, MD.

The data were presented at the recent American Urological Association Annual Meeting.

"From a learning curve standpoint, there's not much to learn. It tends to be fairly quick in terms of your ability to do the procedure," says Matthew E. Sterling, MD.

No statistically significant difference was seen in progression-free survival among those who received metformin vs those who received placebo.